Background: Alcohol use disorder (AUD) is a pervasive disease affecting 28.6 million (11.3%) American adults in 2021.1 Medications for AUD (MAUD), including naltrexone, acamprosate, and disulfiram, are effective, yet less than 5% of these patients received treatment.1,2    Inpatient encounters of patients with AUD present a crucial opportunity to initiate MAUD, prompting this quality improvement [...]